An Omicron-specific, self-amplifying mRNA booster vaccine for ... The event brings together over 900 attendees from both academic institutions and leading pharma and biotech companies. The 2024 ...

Please see the forward-looking statement disclaimer on the company's press release issued earlier today, as well as the risk factors section in our most recent form 10-K and in subsequent ... Meiji ...

The booster shot – called mRNA-1273.211 – offered better and longer-lasting protection compared to the original SpikeVax shot against all SARS-CoV-2 variants, including the prevailing Omicron ...

Request To Download Free Sample of This Strategic Report @- The Global X-ray Photoelectron Spectroscopy (XPS) Market is poised for significant growth, with projections indicating a reach of over USD ...

The facility is the centrepiece of a 10-year agreement-in-principle between ... vaccine candidate against the newer variants like Omicron if authorised, for delivery in 2022 and 2023.

The XEC COVID-19 variant is poised to become the dominant variant worldwide. Now is a good time to get an updated COVID ...

Zealand Pharma A/S briefly reclaimed its position as this year’s ... the Danish biotech firm’s experimental weight-loss drug ...

While A.I. promises breakthroughs, industry leaders warn that transparency and patient safety must remain front and center.

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

Analyst Silvan Tuerkcan of JMP Securities maintained a Buy rating on Terns Pharmaceuticals (TERN – Research Report), retaining the price ...

Main Camera Five 108 MP (7P lens), f/1.7, 25mm (wide), 1/1.33", 0.8µm, PDAF, Laser AF, OIS 12 MP, f/2.0, 50mm (telephoto), 1/2.55", 1.4µm, dual pixel PDAF, 2x ...